Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

Annual and Special Meeting of Shareholders

Jan 27, 2025 • 7:00 am PDT